Key result
Deep vein thrombosis as the index event and ECOG status ≥1 independently predicted recurrent VTE in patients with cancer-associated VTE.
Why the study?
Risks of recurrence and treatment-emergent bleeding are high in patients with cancer-associated VTE, but factors associated with these risks remain substantially undefined.
What are the independent risk factors for recurrent VTE and major bleeding in patients with cancer-associated VTE receiving standardized anticoagulant treatment?
Observational
What are the independent risk factors for recurrent VTE and major bleeding in patients with cancer-associated VTE receiving standardized anticoagulant treatment?
Specific clinical factors, including cancer site and ECOG status, independently predict the risk of recurrent VTE and major bleeding in patients with cancer-associated VTE, which may help tailor anticoagulation therapy.
Answers are grounded in this paper and cite their sources.
May aid recurrence risk stratification by index event and ECOG in cancer VTE; leaves open whether risk-adapted therapy improves outcomes.
Risks of recurrence and treatment-emergent bleeding are high in patients with cancer-associated venous thromboembolism (VTE) but factors associated with these risks remain substantially undefined. The aim of this analysis in patients with cancer-associated VTE included in the Caravaggio study was to identify risk factors for recurrent VTE and major bleeding. Variables potentially predictive for recurrent VTE or major bleeding were evaluated in a Cox proportional hazard multivariable analysis with backward variable selection. Recurrent VTE occurred in 78 patients (6.8%) and major bleeding in 45 (3.9%). Independent risk factors for recurrent VTE were deep vein thrombosis (DVT) as index event (Hazard ratio (HR) 1.84, 95% CI 1.17-2.88), ECOG status of 1 or more (HR 1.95, 95% CI 1.11-3.43), pancreatic or hepatobiliary cancer site (HR 2.20, 95% CI 1.19-4.06), concomitant anti-cancer treatment (HR 1.98, 95% CI 1.03-3.81) and creatinine clearance (HR 1.10, 95% CI 1.00-1.20 for every 10 ml/min absolute increase). Independent risk factors for major bleeding were ECOG status of 2 (HR 2.31, 95% CI 1.24-4.29), genitourinary cancer site (HR 2.72, 95% CI 1.28-5.77), upper gastrointestinal cancer site (HR 3.17, 95% CI 1.22-8.23), and non-resected luminal gastrointestinal cancer (HR 2.77, 95% CI 1.38-5.56). This analysis of the Caravaggio study in patients with cancer-associated VTE who were on standardized anticoagulant treatment identified five independent predictors for recurrent VTE and four independent predictors of treatment-emergent major bleeding. Considering these risks could help clinicians to optimize the anticoagulant treatment in patients with cancer-associated VTE.
No takes yet. Share an insight, caveat, or question.
Vedovati et al. (2023) conducted an observational in Cancer-associated venous thromboembolism. Standardized anticoagulant treatment was evaluated on Recurrent VTE and major bleeding. Deep vein thrombosis as the index event and ECOG status ≥1 independently predicted recurrent VTE in patients with cancer-associated VTE.
Synapse has enriched 10 related papers. Consider them for comparative context: